Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer, Israel Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
J Crohns Colitis. 2023 May 3;17(5):722-727. doi: 10.1093/ecco-jcc/jjac179.
Idiopathic thrombocytopaenic purpura [ITP] is an acquired haematological disorder with an incidence of 1-6 per 100 00/year. ITP and inflammatory bowel disease [IBD] comorbidity has been reported in the literature, but insights regarding the course, outcome and optimal management are limited by its rarity. The current study aimed to evaluate the clinical presentation and outcome of ITP in patients with IBD.
This multicentre retrospective case series was performed as part of the ECCO Collaborative Network of Exceptionally Rare case reports [CONFER] project. Cases of patients with ITP and IBD were collected by participating investigators. Clinical data were recorded in a standardized collection form.
This report includes 32 patients with concurrent ITP and IBD: ten were females, and the median age was 32.0 years (interquartile range [IQR] 20.5-39.5). Fourteen patients had a diagnosis of Crohn's disease [CD] and the other 18 ulcerative colitis [UC]. The diagnosis of IBD preceded the ITP in 26 patients (median time between diagnoses was 7.0 years [IQR, 1.5-9.5]). Among those patients, 17 were in clinical remission at ITP diagnosis. Thirteen patients were treated with mesalamine, four with oral corticosteroids, one with rectal corticosteroids, two with azathioprine and five with anti-tumour necrosis factor agents. The median platelet count was 35 000/microliter [IQR, 10 000-70 000]. Eight patients had rectal bleeding, 13 had skin purpura, three had epistaxis, six had mucosal petechiae and 13 were asymptomatic. Regarding ITP treatment, 19 were treated with corticosteroids, one with anti-RhD immunoglobulin, 12 with intravenous immunoglobulins [IVIGs], four with thrombopoietin, three with rituximab and six patients eventually required splenectomy. Ten patients needed no treatment directed to the ITP. Three patients required colectomy during long-term follow-up, due to IBD or cancer but not to massive bleeding as a complication of ITP. One of eight patients who presented with rectal bleeding required splenectomy, and none required urgent colectomy. Two patients died during the follow-up, one of them due to bleeding complications located in the upper gastrointestinal tract. Median follow-up time was 6.5 years [IQR, 3-10]. With long-term follow-up, all patients had platelet counts above 50 000/microliter, and 24 were in IBD clinical remission.
Most ITP cases in this series occurred after the IBD diagnosis and responded well to regular ITP treatment. The course of the ITP in the IBD patients followed an expected course, including response to medical therapy and low rates of splenectomy.
特发性血小板减少性紫癜(ITP)是一种获得性血液学疾病,发病率为每年每 10 万人 1-6 人。文献中报道了 ITP 与炎症性肠病(IBD)的合并症,但由于其罕见性,对其病程、结局和最佳治疗方法的了解有限。本研究旨在评估 IBD 患者 ITP 的临床表现和结局。
这是一项作为 ECCO 合作网络异常罕见病例报告(CONFER)项目的一部分进行的多中心回顾性病例系列研究。通过参与研究者收集 ITP 和 IBD 并存的患者病例。临床数据记录在标准化收集表中。
本报告包括 32 例 ITP 和 IBD 并存的患者:10 例为女性,中位年龄为 32.0 岁(四分位距 [IQR] 20.5-39.5)。14 例患者诊断为克罗恩病(CD),18 例为溃疡性结肠炎(UC)。26 例患者的 IBD 诊断先于 ITP(诊断之间的中位时间为 7.0 年 [IQR,1.5-9.5])。在这些患者中,17 例在 ITP 诊断时处于临床缓解期。13 例接受了美沙拉嗪治疗,4 例接受了口服皮质类固醇治疗,1 例接受了直肠皮质类固醇治疗,2 例接受了硫唑嘌呤治疗,5 例接受了抗肿瘤坏死因子治疗。血小板计数中位数为 35 000/μL(IQR,10 000-70 000)。8 例患者有直肠出血,13 例有皮肤紫癜,3 例有鼻出血,6 例有黏膜瘀点,13 例无症状。关于 ITP 治疗,19 例接受了皮质类固醇治疗,1 例接受了抗 RhD 免疫球蛋白治疗,12 例接受了静脉注射免疫球蛋白(IVIG)治疗,4 例接受了血小板生成素治疗,3 例接受了利妥昔单抗治疗,6 例患者最终需要脾切除术。10 例患者无需针对 ITP 进行治疗。3 例患者在长期随访中因 IBD 或癌症而需要结肠切除术,但不是因为 ITP 引起的大量出血。8 例有直肠出血的患者中有 1 例需要脾切除术,没有患者需要紧急结肠切除术。2 例患者在随访期间死亡,其中 1 例死于上消化道出血并发症。中位随访时间为 6.5 年(IQR,3-10)。长期随访时,所有患者的血小板计数均超过 50 000/μL,24 例患者处于 IBD 临床缓解期。
本研究系列中的大多数 ITP 病例发生在 IBD 诊断之后,对常规 ITP 治疗反应良好。ITP 在 IBD 患者中的病程符合预期,包括对药物治疗的反应和脾切除术的低发生率。